Prices are updated after-hours

Diabetes

Provention Bio, Inc.

PRVB | $24.98 0.08% 9.1M

(0.0% 1d) (0.0% 1m) (2.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 2,367,626,233
http://www.proventionbio.com
Sec Filling | Patents | 19 employees

(US) Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.

diabetes diabetic treatment

add to watch list Paper trade email alert is off

Sino Biopharmaceutical Limited/ADR

SBMFF | $0.3624 64.18% 45K

Health Technology

(0.0% 1d) (0.0% 1m) (-29.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (19324.79% volume)
Earnings Calendar:
Market Cap: $ 6,813,561,124
http://www.sinobiopharm.com
Sec Filling | Patents | n/a employees

(HK) Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.

respiratory diabetic diabetes

add to watch list Paper trade email alert is off

ConvaTec Group PLC/ADR

CNVVF | $3.685 -18.0% 6.4K

Health Technology

(0.0% 1d) (-3.0% 1m) (31.6% 1y) (0.0% 2d) (0.0% 3d) (-5.0% 7d) (2130.18% volume)
Earnings Calendar:
Market Cap: $ 7,553,474,525
http://www.convatec.com
Sec Filling | Patents | n/a employees

(GB) ConvaTec Group Plc operates as holding company, which engages in medical business. Its activities include development, manufacture and sales of medical products and technologies related to therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care and management, continence and critical care, and infusion devices used in the treatment of diabetes and other conditions. The company was incorporated in 1978 and is headquartered in Reading, the United Kingdom.

treatment diabetic diabetes

add to watch list Paper trade email alert is off

Sigilon Therapeutics Inc

SGTX | $22.47 -2.56% 0.0% 0

Health Technology

(0.0% 1d) (0.0% 1m) (152.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (32.61% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 56,500,770
https://sigilon.com
Sec Filling | Patents | 2021 employees

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

diabetic diabetes ceiling t-cell

add to watch list Paper trade email alert is off

Aadi Biosciences Inc

AADI | $1.79 -2.72% -2.79% 110K

Manufacturing

(0.0% 1d) (-15.2% 1m) (-77.0% 1y) (0.0% 2d) (-3.2% 3d) (0.0% 7d) (-52.04% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 43,952,027
https://www.aerpio.com
Sec Filling | Patents | 12 employees

(US) Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.

monoclonal antibodies antibody treatment diabetic diabetes injection macular

add to watch list Paper trade email alert is off

Genprex, Inc.

GNPX | $2.31 6.77% 20K

Health Technology

(0.0% 1d) (-23.0% 1m) (182.4% 1y) (0.0% 2d) (6.9% 3d) (8.5% 7d) (55.81% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 4,413,119
http://www.genprex.com
Sec Filling | Patents | 8 employees

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

cancer lung cancer gene therapies diabetes diabetic glass food t-cell lungs treatment msa ceiling

add to watch list Paper trade email alert is off

Galmed Pharmaceuticals Ltd.

GLMD | $0.3852 6.59% 6.18% 52K

Health Technology

(0.0% 1d) (12.4% 1m) (-99.5% 1y) (0.0% 2d) (0.0% 3d) (-2.7% 7d) (3.2% volume)
Earnings Calendar: 2022-11-07
Market Cap: $ 1,943,459
http://www.galmedpharma.com
Sec Filling | Patents | 21 employees

(IL) Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

diabetes diabetic israel hepatitis nash treatment

add to watch list Paper trade email alert is off

Humacyte Inc

HUMA | $3.82 -2.8% -2.88% 1.5M

Manufacturing

(0.0% 1d) (25.2% 1m) (15.9% 1y) (0.0% 2d) (6.2% 3d) (9.5% 7d) (-17.74% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 454,899,841
https://humacyte.com
Sec Filling | Patents | n/a employees

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

diabetic diabetes ceiling treatment defense t-cell

add to watch list Paper trade email alert is off

Johnson & Johnson

JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

(0.0% 1d) (-3.8% 1m) (-9.4% 1y) (0.0% 2d) (0.9% 3d) (3.2% 7d) (NaN% volume)
Earnings Calendar: 2024-01-23
Market Cap: $ 357,925,077,011
http://www.jnj.com
Sec Filling | Patents | 132200 employees

(US) Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

vaccine cardiovascular eye infectious disease diabetes diabetic hypertension urea pulmonary hypertension women health immunology metabolic women

add to watch list Paper trade email alert is off

KalVista Pharmaceuticals, Inc.

KALV | News | $10.34 -7.76% -8.41% 420K

Health Technology

(0.0% 1d) (0.7% 1m) (39.3% 1y) (0.0% 2d) (-2.0% 3d) (-2.1% 7d) (-33.45% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 436,226,981
http://www.kalvista.com
Sec Filling | Patents | 56 employees

(US) KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.

diabetes diabetic macular hereditary angioedema

add to watch list Paper trade email alert is off

Intelligent Bio Solutions Inc

INBS | $2.58 -7.19% -7.75% 51K

Manufacturing

(0.0% 1d) (-34.6% 1m) (6.9% 1y) (0.0% 2d) (4.5% 3d) (-0.7% 7d) (-22.0% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 7,338,175
https://gbs.inc
Sec Filling | Patents | 8 employees

(US) GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.

diagnostics diabetes diabetic covid

add to watch list Paper trade email alert is off

SAB Biotherapeutics Inc

SABS | $4.36 7.54% 730

(0.0% 1d) (2.6% 1m) (462.6% 1y) (0.0% 2d) (-0.7% 3d) (1.6% 7d) (-50.72% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 40,223,154
https://www.sabbiotherapeutics.com
Sec Filling | Patents | 5 employees

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

genetic cancer diabetes diabetic influenza covid

add to watch list Paper trade email alert is off

Kodiak Sciences Inc

KOD | News | $3.37 1.2% 1.19% 340K

Health Technology

(0.0% 1d) (-45.6% 1m) (-27.6% 1y) (0.0% 2d) (-2.6% 3d) (-0.9% 7d) (-100.0% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 176,953,989
http://www.kodiak.com
Sec Filling | Patents | 39 employees

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

eye diseases eye diabetes diabetic dmd treatment

add to watch list Paper trade email alert is off

Landos Biopharma Inc

LABP | $22.21 0.27% 0.27% 9.1K

(0.0% 1d) (2.2% 1m) (663.8% 1y) (0.0% 2d) (0.9% 3d) (1.5% 7d) (-30.03% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 69,278,009
https://www.landosbiopharma.com
Sec Filling | Patents | 33 employees

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma’s core expertise is in the development of therapeutic candidates targeting novel pathways at the interface of immunity and metabolism. Lead asset BT-11 is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes.

diabetic diabetes sclerosis treatment metabolic

add to watch list Paper trade email alert is off

Lexicon Pharmaceuticals, Inc.

LXRX | $1.6 -0.62% -0.63% 1.8M

Health Technology

(0.0% 1d) (-24.1% 1m) (-31.8% 1y) (0.0% 2d) (-5.8% 3d) (-2.7% 7d) (-13.0% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 393,978,805
http://www.lexpharma.com
Sec Filling | Patents | 184 employees

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

diabetic diabetes treatment

Drugs

Xermelo (telotristat ethyl)

add to watch list Paper trade email alert is off

Medtronic plc

MDT | $80.38 -1.12% 0.0% 5M

Health Technology

(0.0% 1d) (-2.3% 1m) (-9.4% 1y) (0.0% 2d) (0.9% 3d) (2.3% 7d) (6.72% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 106,730,375,685
http://www.medtronic.com
Sec Filling | Patents | 90000 employees

(US) Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

respiratory heart gastrointestinal diabetes diabetic renal

add to watch list Paper trade email alert is off

Novo Nordisk A/S

NVO | News | $126.16 -1.93% -0.23% 3.1M

Health Technology

(0.0% 1d) (-0.3% 1m) (-23.7% 1y) (0.0% 2d) (2.7% 3d) (4.8% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 433,375,748,480
http://www.novonordisk.com
Sec Filling | Patents | 43258 employees

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

obesity diabetes haemophilia insulin diabetic hormone growth hormone

add to watch list Paper trade email alert is off

Senseonics Holdings, Inc.

SENS | $0.433 0.7% 0.0% 1.4M

Electronic Technology

(0.0% 1d) (-24.1% 1m) (-27.4% 1y) (0.0% 2d) (7.5% 3d) (2.4% 7d) (-23.26% volume)
Earnings Calendar:
Market Cap: $ 229,843,999
http://www.senseonics.com
Sec Filling | Patents | 191 employees

(US) Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

diabetes diabetic brands monitoring device sensor

add to watch list Paper trade email alert is off

PetMed Express, Inc.

PETS | $4.13 -0.48% -0.48% 260K

Retail Trade

(0.0% 1d) (-12.8% 1m) (-72.6% 1y) (0.0% 2d) (2.5% 3d) (1.0% 7d) (-31.98% volume)
Earnings Calendar: 2024-03-29
Market Cap: $ 87,344,098
http://www.1800petmeds.com
Sec Filling | Patents | 214 employees

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

nutrition heart diabetes diabetic pets bone

add to watch list Paper trade email alert is off

Insulet Corporation

PODD | $167.215 -0.03% -0.03% 650K

Health Technology

(0.0% 1d) (1.5% 1m) (-47.9% 1y) (0.0% 2d) (1.7% 3d) (0.6% 7d) (-18.88% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 11,708,811,167
http://www.insulet.com
Sec Filling | Patents | 1350 employees

(US) Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

insulin diabetes diabetic

add to watch list Paper trade email alert is off